A Phase 2 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-30.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 30th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 2, and was the 4th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2010.
This study's enrollment of 123 is below the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 30th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2010, is one of 8 in phase 2, and was the 8th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts.
This Protocol Posting has been updated following Amendment 1 of the Protocol, August 2010. The impacted sections is exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;
For the antiretroviral therapyART High CD4 and ART Low CD4 cohorts:
For the non-ART High CD4 cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
Biological: Herpes Zoster Vaccine GSK1437173A
Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
Biological: Placebo
intramuscular injection
Also known as: HZ/su vaccine
intramuscular injection
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 to Month 18
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From screening (up to 21 days prior to Month 0) until Month 18
Number of Subjects With Any Fatal SAEs
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From screening (up to 21 days prior to Month 0) until Month 18
Number of Subjects With Any Adverse Events (AEs) of Specific Interest
AEs of specific interest include new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders from administration of the first dose of vaccine/placebo.
Time frame: From Month 0 until Month 18
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of their intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral/axillary temperature above (\>) 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of their intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days (Days 0-29) after each vaccination
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
Time frame: At Screening Visit (up to 21 days prior to Month 0)
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
Time frame: At Month 1
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
Time frame: At Month 2
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.
Time frame: At Month 3
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
Time frame: At Month 6
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.
Time frame: At Month 7
Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects
In this analysis, results were tabulated for the main study groups. Significant changes to ART appeared due to failure to control HIV viral load and due to failure to maintain high CD4 cells count.
Time frame: From Month 0 until Month 18
Number of Subjects With Any AIDS-defining Condition
In this analysis, results were tabulated for the main study groups.
Time frame: From Month 0 until Month 18
Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count
In this analysis, results were tabulated for the main study groups.
Time frame: From Month 1 to Month 7
Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects, by HIV Status
In this analysis, results were tabulated by HIV status
Time frame: From Month 0 to Month 18
Number of Subjects With Any AIDS-defining Condition, by HIV Status
In this analysis, results were tabulated by HIV status
Time frame: From Month 0 to Month 18
Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count, by HIV Status
In this analysis, results were tabulated by HIV status.
Time frame: From Month 1 to Month 7
Frequency of gE-specific CD4 T-cells
The analysis focused on CD4 T-cells expressing at least 2 cytokines (among interferon-gamma (IFN-g) , interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-a) and/or CD40 ligand (CD40L)) as determined by in vitro intracellular cytokine staining (ICS) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrollment.
Time frame: At Month 7
-Anti-gE Antibody (Ab) Concentrations
-Anti-gE antibody (Ab) concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrolment. Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 7
-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells
The analysis focused on CD4 T cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated for the main study groups.
Time frame: At Month 0, 1, 2, 3, 6, 7 and 18
-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells, by HIV Status
The analysis focused on CD4 T-cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated by HIV status.
Time frame: At Months 0, 1, 2, 3, 6, 7 and 18
-Anti-VZV and Anti-gE Antibody Concentrations
Antibody concentrations were as determined by ELISA and tabulated for the main study groups. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.
Time frame: At Months 0, 1, 2, 3, 6, 7 and 18
-Anti-VZV and Anti-gE Antibody Concentrations, by HIV Status
Antibody concentrations were as determined by ELISA and tabulated by HIV status. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.
Time frame: At Months 0, 1, 2, 3, 6, 7 and 18
Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications
Time frame: From Month 0 until Month 18
CD4 Count
CD4 count was tabulated by HIV status.
Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18
HIV VL
HIV VL was tabulated by HIV status, for subjects with a number of available results greater than or equal to (≥) 40 copies/mL.
Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 74 | 49 |
| Completed | 69 | 47 |
| Not completed | 5 | 2 |
| Withdrew: Serious adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Migrated/moved from study area | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 74 | 49 |
| Completed | 67 | 45 |
| Not completed | 7 | 4 |
| Withdrew: Serious adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Migrated/moved from study area | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Other-subjects business reasons | 0 | 1 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 6 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine | 0 | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Fatal SAEs | 0 | 0 |
AEs of specific interest include new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders from administration of the first dose of vaccine/placebo.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Adverse Events (AEs) of Specific Interest | 0 | 0 |
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of their intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 69 | 4 |
| Grade 3 Pain, Dose 1 | 4 | 0 |
| Any Redness, Dose 1 | 17 | 0 |
| Grade 3 Redness, Dose 1 | 2 | 0 |
| Any Swelling, Dose 1 | 12 | 0 |
| Grade 3 Swelling, Dose 1 | 1 | 0 |
| Any Pain, Dose 2 | 57 | 3 |
| Grade 3 Pain, Dose 2 | 8 | 0 |
| Any Redness, Dose 2 | 19 | 0 |
| Grade 3 Redness, Dose 2 | 1 | 0 |
| Any Swelling, Dose 2 | 11 | 0 |
| Grade 3 Swelling, Dose 2 | 0 | 0 |
| Any Pain, Dose 3 | 43 | 1 |
| Grade 3 Pain, Dose 3 | 7 | 0 |
| Any Redness, Dose 3 | 9 | 0 |
| Grade 3 Redness, Dose 3 | 2 | 0 |
| Any Swelling, Dose 3 | 5 | 0 |
| Grade 3 Swelling, Dose 3 | 0 | 0 |
| Any Pain, Across doses | 72 | 6 |
| Grade 3 Pain, Across doses | 12 | 0 |
| Any Redness, Across doses | 28 | 0 |
| Grade 3 Redness, Across doses | 4 | 0 |
| Any Swelling, Across doses | 20 | 0 |
| Grade 3 Swelling, Across doses | 1 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral/axillary temperature above (\>) 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of their intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 30 | 13 |
| Grade 3 Fatigue, Dose 1 | 0 | 3 |
| Related Fatigue, Dose 1 | 17 | 8 |
| Any Gastrointestinal, Dose 1 | 13 | 8 |
| Grade 3 Gastrointestinal, Dose 1 | 0 | 0 |
| Related Gastrointestinal, Dose 1 | 6 | 6 |
| Any Headache, Dose 1 | 25 | 10 |
| Grade 3 Headache, Dose 1 | 0 | 1 |
| Related Headache, Dose 1 | 16 | 6 |
| Any Myalgia, Dose 1 | 34 | 6 |
| Grade 3 Myalgia, Dose 1 | 4 | 0 |
| Related Myalgia, Dose 1 | 26 | 6 |
| Any Shivering, Dose 1 | 19 | 5 |
| Grade 3 Shivering, Dose 1 | 0 | 0 |
| Related Shivering, Dose 1 | 11 | 5 |
| Any Temperature, Dose 1 | 7 | 2 |
| Grade 3 Temperature, Dose 1 | 0 | 0 |
| Related Temperature, Dose 1 | 2 | 2 |
| Any Fatigue, Dose 2 | 41 | 8 |
| Grade 3 Fatigue, Dose 2 | 7 | 3 |
| Related Fatigue, Dose 2 | 25 | 5 |
| Any Gastrointestinal, Dose 2 | 18 | 3 |
| Grade 3 Gastrointestinal, Dose 2 | 1 | 1 |
| Related Gastrointestinal, Dose 2 | 8 | 1 |
| Any Headache, Dose 2 | 32 | 3 |
| Grade 3 Headache, Dose 2 | 3 | 0 |
| Related Headache, Dose 2 | 18 | 1 |
| Any Myalgia, Dose 2 | 33 | 4 |
| Grade 3 Myalgia, Dose 2 | 1 | 1 |
| Related Myalgia, Dose 2 | 24 | 2 |
| Any Shivering, Dose 2 | 23 | 1 |
| Grade 3 Shivering, Dose 2 | 4 | 0 |
| Related Shivering, Dose 2 | 17 | 1 |
| Any Temperature, Dose 2 | 12 | 1 |
| Grade 3 Temperature, Dose 2 | 0 | 0 |
| Related Temperature, Dose 2 | 10 | 0 |
| Any Fatigue, Dose 3 | 36 | 6 |
| Grade 3 Fatigue, Dose 3 | 7 | 1 |
| Related Fatigue, Dose 3 | 24 | 3 |
| Any Gastrointestinal, Dose 3 | 8 | 4 |
| Grade 3 Gastrointestinal, Dose 3 | 1 | 0 |
| Related Gastrointestinal, Dose 3 | 5 | 2 |
| Any Headache, Dose 3 | 33 | 7 |
| Grade 3 Headache, Dose 3 | 4 | 1 |
| Related Headache, Dose 3 | 21 | 3 |
| Any Myalgia, Dose 3 | 32 | 1 |
| Grade 3 Myalgia, Dose 3 | 6 | 0 |
| Related Myalgia, Dose 3 | 22 | 1 |
| Any Shivering, Dose 3 | 20 | 1 |
| Grade 3 Shivering, Dose 3 | 7 | 0 |
| Related Shivering, Dose 3 | 14 | 1 |
| Any Temperature, Dose 3 | 11 | 1 |
| Grade 3 Temperature, Dose 3 | 0 | 0 |
| Related Temperature, Dose 3 | 6 | 0 |
| Any Fatigue, Across doses | 55 | 14 |
| Grade 3 Fatigue, Across doses | 12 | 4 |
| Related Fatigue, Across doses | 41 | 8 |
| Any Gastrointestinal, Across doses | 28 | 11 |
| Grade 3 Gastrointestinal, Across doses | 2 | 1 |
| Related Gastrointestinal, Across doses | 16 | 7 |
| Any Headache, Across doses | 47 | 15 |
| Grade 3 Headache, Across doses | 6 | 2 |
| Related Headache, Across doses | 34 | 8 |
| Any Myalgia, Across doses | 54 | 9 |
| Grade 3 Myalgia, Across doses | 10 | 1 |
| Related Myalgia, Across doses | 44 | 8 |
| Any Shivering, Across doses | 37 | 5 |
| Grade 3 Shivering, Across doses | 11 | 0 |
| Related Shivering, Across doses | 29 | 5 |
| Any Temperature, Across doses | 22 | 3 |
| Grade 3 Temperature, Across doses | 0 | 0 |
| Related Temperature, Across doses | 17 | 2 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any AE(s) | 41 | 26 |
| Grade 3 AE(s) | 4 | 2 |
| Related AE(s) | 11 | 3 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 0 | 0 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 70 | 41 |
| Alanine Aminotransferase — Above | 4 | 8 |
| Albumin — Unknown | 0 | 0 |
| Albumin — Below | 0 | 0 |
| Albumin — Within | 72 | 47 |
| Albumin — Above | 2 | 2 |
| Alkaline Phosphatase — Unknown | 0 | 0 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 70 | 44 |
| Alkaline Phosphatase — Above | 4 | 5 |
| Aspartate Aminotransferase — Unknown | 0 | 0 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 69 | 45 |
| Aspartate Aminotransferase — Above | 5 | 4 |
| Basophils — Unknown | 0 | 0 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 74 | 49 |
| Basophils — Above | 0 | 0 |
| White Blood Cells — Unknown | 1 | 0 |
| White Blood Cells — Below | 3 | 0 |
| White Blood Cells — Within | 69 | 47 |
| White Blood Cells — Above | 1 | 2 |
| Total Bilirubin — Unknown | 0 | 0 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 65 | 46 |
| Total Bilirubin — Above | 9 | 3 |
| Bilirubin Conjugated / Direct — Unknown | 0 | 0 |
| Bilirubin Conjugated / Direct — Below | 0 | 0 |
| Bilirubin Conjugated / Direct — Within | 73 | 49 |
| Bilirubin Conjugated / Direct — Above | 1 | 0 |
| Creatinine — Unknown | 0 | 0 |
| Creatinine — Below | 6 | 8 |
| Creatinine — Within | 68 | 40 |
| Creatinine — Above | 0 | 1 |
| Eosinophils — Unknown | 0 | 0 |
| Eosinophils — Below | 14 | 10 |
| Eosinophils — Within | 59 | 38 |
| Eosinophils — Above | 1 | 1 |
| Glucose — Unknown | 0 | 0 |
| Glucose — Below | 0 | 1 |
| Glucose — Within | 69 | 43 |
| Glucose — Above | 5 | 5 |
| Bicarbonate — Unknown | 0 | 0 |
| Bicarbonate — Below | 5 | 2 |
| Bicarbonate — Within | 69 | 47 |
| Bicarbonate — Above | 0 | 0 |
| Haemoglobin — Unknown | 0 | 0 |
| Haemoglobin — Below | 13 | 5 |
| Haemoglobin — Within | 58 | 42 |
| Haemoglobin — Above | 3 | 2 |
| Potassium — Unknown | 0 | 0 |
| Potassium — Below | 0 | 0 |
| Potassium — Within | 74 | 49 |
| Potassium — Above | 0 | 0 |
| Lymphocytes — Unknown | 0 | 0 |
| Lymphocytes — Below | 0 | 1 |
| Lymphocytes — Within | 74 | 48 |
| Lymphocytes — Above | 0 | 0 |
| Monocytes — Unknown | 0 | 0 |
| Monocytes — Below | 2 | 4 |
| Monocytes — Within | 71 | 45 |
| Monocytes — Above | 1 | 0 |
| Sodium — Unknown | 0 | 0 |
| Sodium — Below | 1 | 0 |
| Sodium — Within | 73 | 49 |
| Sodium — Above | 0 | 0 |
| Neutrophils — Unknown | 0 | 0 |
| Neutrophils — Below | 5 | 3 |
| Neutrophils — Within | 69 | 45 |
| Neutrophils — Above | 0 | 1 |
| Platelets — Unknown | 0 | 0 |
| Platelets — Below | 4 | 1 |
| Platelets — Within | 70 | 48 |
| Platelets — Above | 0 | 0 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 0 | 0 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 67 | 41 |
| Alanine Aminotransferase — Above | 6 | 4 |
| Albumin — Unknown | 0 | 0 |
| Albumin — Below | 0 | 0 |
| Albumin — Within | 69 | 43 |
| Albumin — Above | 4 | 2 |
| Alkaline Phosphatase — Unknown | 0 | 0 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 71 | 43 |
| Alkaline Phosphatase — Above | 2 | 2 |
| Aspartate Aminotransferase — Unknown | 0 | 0 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 69 | 42 |
| Aspartate Aminotransferase — Above | 4 | 3 |
| Basophils — Unknown | 1 | 0 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 72 | 45 |
| Basophils — Above | 0 | 0 |
| Total Bilirubin — Unknown | 0 | 0 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 65 | 42 |
| Total Bilirubin — Above | 8 | 3 |
| Bilirubin Conjugated/Direct — Unknown | 0 | 0 |
| Bilirubin Conjugated/Direct — Below | 0 | 0 |
| Bilirubin Conjugated/Direct — Within | 73 | 44 |
| Bilirubin Conjugated/Direct — Above | 0 | 1 |
| Creatinine — Unknown | 0 | 0 |
| Creatinine — Below | 4 | 7 |
| Creatinine — Within | 66 | 38 |
| Creatinine — Above | 3 | 0 |
| Eosinophils — Unknown | 1 | 0 |
| Eosinophils — Below | 13 | 6 |
| Eosinophils — Within | 57 | 39 |
| Eosinophils — Above | 2 | 0 |
| Glucose — Unknown | 0 | 0 |
| Glucose — Below | 2 | 1 |
| Glucose — Within | 62 | 34 |
| Glucose — Above | 9 | 10 |
| Bicarbonate — Unknown | 0 | 0 |
| Bicarbonate — Below | 7 | 1 |
| Bicarbonate — Within | 66 | 44 |
| Bicarbonate — Above | 0 | 0 |
| Haemoglobin — Unknown | 1 | 0 |
| Haemoglobin — Below | 12 | 3 |
| Haemoglobin — Within | 57 | 40 |
| Haemoglobin — Above | 3 | 2 |
| Potassium — Unknown | 0 | 0 |
| Potassium — Below | 0 | 1 |
| Potassium — Within | 73 | 44 |
| Potassium — Above | 0 | 0 |
| Lymphocytes — Unknown | 1 | 0 |
| Lymphocytes — Below | 1 | 0 |
| Lymphocytes — Within | 71 | 45 |
| Lymphocytes — Above | 0 | 0 |
| Monocytes — Unknown | 1 | 0 |
| Monocytes — Below | 6 | 3 |
| Monocytes — Within | 66 | 42 |
| Monocytes — Above | 0 | 0 |
| Sodium — Unknown | 0 | 0 |
| Sodium — Below | 0 | 1 |
| Sodium — Within | 73 | 44 |
| Sodium — Above | 0 | 0 |
| Neutrophils — Unknown | 1 | 0 |
| Neutrophils — Below | 8 | 3 |
| Neutrophils — Within | 64 | 40 |
| Neutrophils — Above | 0 | 2 |
| Platelets — Unknown | 1 | 0 |
| Platelets — Below | 2 | 3 |
| Platelets — Within | 70 | 42 |
| Platelets — Above | 0 | 0 |
| White Blood Cells — Unknown | 1 | 0 |
| White Blood Cells — Below | 5 | 4 |
| White Blood Cells — Within | 67 | 39 |
| White Blood Cells — Above | 0 | 2 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 0 | 1 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 67 | 40 |
| Alanine Aminotransferase — Above | 4 | 6 |
| Albumin — Unknown | 0 | 1 |
| Albumin — Below | 0 | 0 |
| Albumin — Within | 67 | 44 |
| Albumin — Above | 4 | 2 |
| Alkaline Phosphatase — Unknown | 0 | 1 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 68 | 42 |
| Alkaline Phosphatase — Above | 3 | 4 |
| Aspartate Aminotransferase — Unknown | 0 | 1 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 67 | 43 |
| Aspartate Aminotransferase — Above | 4 | 3 |
| Basophils — Unknown | 1 | 2 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 70 | 45 |
| Basophils — Above | 0 | 0 |
| Total Bilirubin — Unknown | 0 | 1 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 64 | 44 |
| Total Bilirubin — Above | 7 | 2 |
| Bilirubin Conjugated/Direct — Unknown | 0 | 1 |
| Bilirubin Conjugated/Direct — Below | 0 | 0 |
| Bilirubin Conjugated/Direct — Within | 69 | 46 |
| Bilirubin Conjugated/Direct — Above | 2 | 0 |
| Creatinine — Unknown | 0 | 1 |
| Creatinine — Below | 5 | 7 |
| Creatinine — Within | 65 | 39 |
| Creatinine — Above | 1 | 0 |
| Eosinophils — Unknown | 1 | 2 |
| Eosinophils — Below | 9 | 7 |
| Eosinophils — Within | 61 | 37 |
| Eosinophils — Above | 0 | 1 |
| Glucose — Unknown | 0 | 1 |
| Glucose — Below | 2 | 0 |
| Glucose — Within | 59 | 38 |
| Glucose — Above | 10 | 8 |
| Bicarbonate — Unknown | 0 | 1 |
| Bicarbonate — Below | 2 | 0 |
| Bicarbonate — Within | 69 | 46 |
| Bicarbonate — Above | 0 | 0 |
| Haemoglobin — Unknown | 1 | 2 |
| Haemoglobin — Below | 15 | 5 |
| Haemoglobin — Within | 53 | 38 |
| Haemoglobin — Above | 2 | 2 |
| Potassium — Unknown | 0 | 1 |
| Potassium — Below | 0 | 0 |
| Potassium — Within | 70 | 46 |
| Potassium — Above | 1 | 0 |
| Lymphocytes — Unknown | 1 | 2 |
| Lymphocytes — Below | 0 | 1 |
| Lymphocytes — Within | 68 | 44 |
| Lymphocytes — Above | 2 | 0 |
| Monocytes — Unknown | 1 | 2 |
| Monocytes — Below | 4 | 4 |
| Monocytes — Within | 66 | 41 |
| Monocytes — Above | 0 | 0 |
| Sodium — Unknown | 0 | 1 |
| Sodium — Below | 0 | 0 |
| Sodium — Within | 70 | 46 |
| Sodium — Above | 1 | 0 |
| Neutrophils — Unknown | 1 | 2 |
| Neutrophils — Below | 7 | 1 |
| Neutrophils — Within | 63 | 43 |
| Neutrophils — Above | 0 | 1 |
| Platelets — Unknown | 1 | 2 |
| Platelets — Below | 1 | 2 |
| Platelets — Within | 69 | 43 |
| Platelets — Above | 0 | 0 |
| White Blood Cells — Unknown | 1 | 2 |
| White Blood Cells — Below | 6 | 2 |
| White Blood Cells — Within | 64 | 41 |
| White Blood Cells — Above | 0 | 2 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 1 | 2 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 66 | 36 |
| Alanine Aminotransferase — Above | 5 | 9 |
| Albumin — Unknown | 1 | 2 |
| Albumin — Below | 0 | 0 |
| Albumin — Within | 67 | 43 |
| Albumin — Above | 4 | 2 |
| Alkaline Phosphatase — Unknown | 1 | 2 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 67 | 40 |
| Alkaline Phosphatase — Above | 4 | 5 |
| Aspartate Aminotransferase — Unknown | 1 | 2 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 68 | 41 |
| Aspartate Aminotransferase — Above | 3 | 4 |
| Basophils — Unknown | 0 | 1 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 72 | 46 |
| Basophils — Above | 0 | 0 |
| Total Bilirubin — Unknown | 1 | 2 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 61 | 43 |
| Total Bilirubin — Above | 10 | 2 |
| Bilirubin Conjugated/Direct — Unknown | 1 | 2 |
| Bilirubin Conjugated/Direct — Below | 0 | 0 |
| Bilirubin Conjugated/Direct — Within | 70 | 44 |
| Bilirubin Conjugated/Direct — Above | 1 | 1 |
| Creatinine — Unknown | 1 | 2 |
| Creatinine — Below | 5 | 7 |
| Creatinine — Within | 66 | 37 |
| Creatinine — Above | 0 | 1 |
| Eosinophils — Unknown | 0 | 1 |
| Eosinophils — Below | 12 | 5 |
| Eosinophils — Within | 59 | 41 |
| Eosinophils — Above | 1 | 0 |
| Glucose — Unknown | 1 | 2 |
| Glucose — Below | 2 | 0 |
| Glucose — Within | 62 | 38 |
| Glucose — Above | 7 | 7 |
| Bicarbonate — Unknown | 1 | 2 |
| Bicarbonate — Below | 5 | 2 |
| Bicarbonate — Within | 66 | 43 |
| Bicarbonate — Above | 0 | 0 |
| Haemoglobin — Unknown | 0 | 1 |
| Haemoglobin — Below | 14 | 5 |
| Haemoglobin — Within | 57 | 37 |
| Haemoglobin — Above | 1 | 4 |
| Potassium — Unknown | 1 | 2 |
| Potassium — Below | 0 | 0 |
| Potassium — Within | 71 | 45 |
| Potassium — Above | 0 | 0 |
| Lymphocytes — Unknown | 0 | 1 |
| Lymphocytes — Below | 0 | 0 |
| Lymphocytes — Within | 72 | 46 |
| Lymphocytes — Above | 0 | 0 |
| Monocytes — Unknown | 0 | 1 |
| Monocytes — Below | 6 | 6 |
| Monocytes — Within | 66 | 40 |
| Monocytes — Above | 0 | 0 |
| Sodium — Unknown | 1 | 2 |
| Sodium — Below | 0 | 0 |
| Sodium — Within | 71 | 45 |
| Sodium — Above | 0 | 0 |
| Neutrophils — Unknown | 0 | 1 |
| Neutrophils — Below | 6 | 5 |
| Neutrophils — Within | 66 | 39 |
| Neutrophils — Above | 0 | 2 |
| Platelets — Unknown | 0 | 1 |
| Platelets — Below | 3 | 2 |
| Platelets — Within | 69 | 44 |
| Platelets — Above | 0 | 0 |
| White Blood Cells — Unknown | 0 | 1 |
| White Blood Cells — Below | 5 | 7 |
| White Blood Cells — Within | 67 | 37 |
| White Blood Cells — Above | 0 | 2 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 0 | 0 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 67 | 41 |
| Alanine Aminotransferase — Above | 4 | 6 |
| Albumin — Unknown | 0 | 0 |
| Albumin — Below | 0 | 0 |
| Albumin — Within | 68 | 44 |
| Albumin — Above | 3 | 3 |
| Alkaline Phosphatase — Unknown | 0 | 0 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 67 | 42 |
| Alkaline Phosphatase — Above | 4 | 5 |
| Aspartate Aminotransferase — Unknown | 0 | 0 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 66 | 45 |
| Aspartate Aminotransferase — Above | 5 | 2 |
| Basophils — Unknown | 2 | 1 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 69 | 46 |
| Basophils — Above | 0 | 0 |
| Total Bilirubin — Unknown | 0 | 0 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 60 | 45 |
| Total Bilirubin — Above | 11 | 2 |
| Bilirubin Conjugated/Direct — Unknown | 0 | 0 |
| Bilirubin Conjugated/Direct — Below | 0 | 0 |
| Bilirubin Conjugated/Direct — Within | 68 | 46 |
| Bilirubin Conjugated/Direct — Above | 3 | 1 |
| Creatinine — Unknown | 0 | 0 |
| Creatinine — Below | 7 | 7 |
| Creatinine — Within | 62 | 39 |
| Creatinine — Above | 2 | 1 |
| Eosinophils — Unknown | 2 | 1 |
| Eosinophils — Below | 13 | 9 |
| Eosinophils — Within | 55 | 36 |
| Eosinophils — Above | 1 | 1 |
| Glucose — Unknown | 0 | 0 |
| Glucose — Below | 1 | 1 |
| Glucose — Within | 62 | 37 |
| Glucose — Above | 8 | 9 |
| Bicarbonate — Unknown | 0 | 0 |
| Bicarbonate — Below | 7 | 7 |
| Bicarbonate — Within | 63 | 40 |
| Bicarbonate — Above | 1 | 0 |
| Haemoglobin — Unknown | 2 | 1 |
| Haemoglobin — Below | 13 | 6 |
| Haemoglobin — Within | 55 | 37 |
| Haemoglobin — Above | 1 | 3 |
| Potassium — Unknown | 0 | 0 |
| Potassium — Below | 0 | 0 |
| Potassium — Within | 70 | 47 |
| Potassium — Above | 0 | 0 |
| Lymphocytes — Unknown | 2 | 1 |
| Lymphocytes — Below | 4 | 3 |
| Lymphocytes — Within | 65 | 42 |
| Lymphocytes — Above | 0 | 1 |
| Monocytes — Unknown | 2 | 1 |
| Monocytes — Below | 2 | 4 |
| Monocytes — Within | 67 | 42 |
| Monocytes — Above | 0 | 0 |
| Sodium — Unknown | 0 | 0 |
| Sodium — Below | 0 | 0 |
| Sodium — Within | 71 | 47 |
| Sodium — Above | 0 | 0 |
| Neutrophils — Unknown | 2 | 1 |
| Neutrophils — Below | 5 | 5 |
| Neutrophils — Within | 64 | 37 |
| Neutrophils — Above | 0 | 4 |
| Platelets — Unknown | 2 | 1 |
| Platelets — Below | 2 | 2 |
| Platelets — Within | 67 | 44 |
| Platelets — Above | 0 | 0 |
| White Blood Cells — Unknown | 2 | 1 |
| White Blood Cells — Below | 6 | 4 |
| White Blood Cells — Within | 62 | 39 |
| White Blood Cells — Above | 1 | 3 |
The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Alanine Aminotransferase — Unknown | 1 | 1 |
| Alanine Aminotransferase — Below | 0 | 0 |
| Alanine Aminotransferase — Within | 64 | 42 |
| Alanine Aminotransferase — Above | 3 | 4 |
| Albumin — Unknown | 1 | 1 |
| Albumin — Below | 0 | 1 |
| Albumin — Within | 64 | 41 |
| Albumin — Above | 3 | 4 |
| Alkaline Phosphatase — Unknown | 1 | 1 |
| Alkaline Phosphatase — Below | 0 | 0 |
| Alkaline Phosphatase — Within | 63 | 42 |
| Alkaline Phosphatase — Above | 4 | 4 |
| Aspartate Aminotransferase — Unknown | 1 | 1 |
| Aspartate Aminotransferase — Below | 0 | 0 |
| Aspartate Aminotransferase — Within | 65 | 43 |
| Aspartate Aminotransferase — Above | 2 | 3 |
| Basophils — Unknown | 0 | 0 |
| Basophils — Below | 0 | 0 |
| Basophils — Within | 68 | 47 |
| Basophils — Above | 0 | 0 |
| Total Bilirubin — Unknown | 1 | 1 |
| Total Bilirubin — Below | 0 | 0 |
| Total Bilirubin — Within | 57 | 43 |
| Total Bilirubin — Above | 10 | 3 |
| Bilirubin Conjugated/Direct — Unknown | 1 | 1 |
| Bilirubin Conjugated/Direct — Below | 0 | 0 |
| Bilirubin Conjugated/Direct — Within | 67 | 46 |
| Bilirubin Conjugated/Direct — Above | 0 | 0 |
| Creatinine — Unknown | 1 | 1 |
| Creatinine — Below | 7 | 6 |
| Creatinine — Within | 57 | 39 |
| Creatinine — Above | 3 | 1 |
| Eosinophils — Unknown | 0 | 0 |
| Eosinophils — Below | 11 | 7 |
| Eosinophils — Within | 56 | 39 |
| Eosinophils — Above | 1 | 1 |
| Glucose — Unknown | 1 | 1 |
| Glucose — Below | 0 | 0 |
| Glucose — Within | 63 | 39 |
| Glucose — Above | 4 | 7 |
| Bicarbonate — Unknown | 1 | 1 |
| Bicarbonate — Below | 6 | 4 |
| Bicarbonate — Within | 61 | 42 |
| Bicarbonate — Above | 0 | 0 |
| Haemoglobin — Unknown | 0 | 0 |
| Haemoglobin — Below | 19 | 6 |
| Haemoglobin — Within | 49 | 40 |
| Haemoglobin — Above | 0 | 1 |
| Potassium — Unknown | 1 | 1 |
| Potassium — Below | 1 | 0 |
| Potassium — Within | 66 | 46 |
| Potassium — Above | 0 | 0 |
| Lymphocytes — Unknown | 0 | 0 |
| Lymphocytes — Below | 0 | 1 |
| Lymphocytes — Within | 67 | 46 |
| Lymphocytes — Above | 1 | 0 |
| Monocytes — Unknown | 0 | 0 |
| Monocytes — Below | 5 | 2 |
| Monocytes — Within | 63 | 45 |
| Monocytes — Above | 0 | 0 |
| Sodium — Unknown | 1 | 1 |
| Sodium — Below | 0 | 0 |
| Sodium — Within | 67 | 46 |
| Sodium — Above | 0 | 0 |
| Neutrophils — Unknown | 0 | 0 |
| Neutrophils — Below | 7 | 1 |
| Neutrophils — Within | 61 | 44 |
| Neutrophils — Above | 0 | 2 |
| Platelets — Unknown | 0 | 0 |
| Platelets — Below | 2 | 1 |
| Platelets — Within | 66 | 46 |
| Platelets — Above | 0 | 0 |
| White Blood Cells — Unknown | 0 | 0 |
| White Blood Cells — Below | 6 | 1 |
| White Blood Cells — Within | 62 | 44 |
| White Blood Cells — Above | 0 | 2 |
In this analysis, results were tabulated for the main study groups. Significant changes to ART appeared due to failure to control HIV viral load and due to failure to maintain high CD4 cells count.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Failure to control HIV viral load | 0 | 0 |
| Failure to maintain high CD4 cells count | 0 | 0 |
In this analysis, results were tabulated for the main study groups.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any AIDS-defining Condition | 0 | 0 |
In this analysis, results were tabulated for the main study groups.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Change in HIV viral load | 3 | 1 |
| Change in CD4 cells count | 7 | 4 |
In this analysis, results were tabulated by HIV status
| Participants | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| Due to failure to control HIV viral load | 0 | 0 | 0 | 0 | 0 | 0 |
| Due to failure to maintain high CD4 cells count | 0 | 0 | 0 | 0 | 0 | 0 |
In this analysis, results were tabulated by HIV status
| Participants | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| Number of Subjects With Any AIDS-defining Condition, by HIV Status | 0 | 0 | 0 | 0 | 0 | 0 |
In this analysis, results were tabulated by HIV status.
| Participants | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| Change in HIV viral load | 1 | 0 | 1 | 0 | 1 | 1 |
| Change in CD4 cells count | 5 | 3 | 1 | 1 | 1 | 0 |
The analysis focused on CD4 T-cells expressing at least 2 cytokines (among interferon-gamma (IFN-g) , interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-a) and/or CD40 ligand (CD40L)) as determined by in vitro intracellular cytokine staining (ICS) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrollment.
| CD4 T-cells/million T-cells | GSK1437173A Group | Placebo Group |
|---|---|---|
| Frequency of gE-specific CD4 T-cells | 4684.50 ± 5376.83 | 158.64 ± 151.15 |
-Anti-gE antibody (Ab) concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrolment. Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| -Anti-gE Antibody (Ab) Concentrations | 63812.6 (51183.6 to 79557.7) | 1028.4 (658.9 to 1605.0) |
The analysis focused on CD4 T cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated for the main study groups.
| CD4 T-cells/million T-cells | GSK1437173A Group | Placebo Group |
|---|---|---|
| VZV-specific CD4 [2+] T-cells, pre-vaccination | 750.20 ± 989.36 | 835.80 ± 1949.39 |
| VZV-specific CD4 [2+] T-cells, Month 1 | 768.60 ± 739.68 | 913.87 ± 2262.66 |
| VZV-specific CD4 [2+] T-cells, Month 2 | 734.09 ± 680.34 | 874.13 ± 2027.95 |
| VZV-specific CD4 [2+] T-cells, Month 3 | 1878.81 ± 1615.20 | 987.24 ± 1988.86 |
| VZV-specific CD4 [2+] T-cells, Month 6 | 1646.83 ± 1202.32 | 674.20 ± 657.00 |
| VZV-specific CD4 [2+] T-cells, Month 7 | 2626.71 ± 2514.40 | 1204.44 ± 1911.53 |
| VZV-specific CD4 [2+] T-cells, Month 18 | 995.35 ± 842.96 | 531.24 ± 579.63 |
| gE-specific CD4 [2+] T-cells, pre-vaccination | 218.26 ± 254.94 | 123.15 ± 170.79 |
| gE-specific CD4 [2+] T-cells, Month 1 | 704.06 ± 614.49 | 132.49 ± 213.05 |
| gE-specific CD4 [2+] T-cells, Month 2 | 649.68 ± 555.51 | 140.95 ± 197.99 |
| gE-specific CD4 [2+] T-cells, Month 3 | 3503.69 ± 2971.74 | 160.10 ± 220.32 |
| gE-specific CD4 [2+] T-cells, Month 6 | 2647.71 ± 1972.00 | 133.70 ± 137.94 |
| gE-specific CD4 [2+] T-cells, Month 7 | 4684.50 ± 5376.83 | 158.64 ± 151.15 |
| gE-specific CD4 [2+] T-cells, Month 18 | 1929.30 ± 1603.50 | 139.50 ± 219.57 |
The analysis focused on CD4 T-cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated by HIV status.
| CD4 T-cells/million T-cells | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| VZV-specific CD4 [2+] T-cells, pre-vaccination | 789.48 ± 1037.59 | 927.27 ± 2053.32 | 1.00 ± 0.00 | 86.96 ± NA | 896.13 ± 749.70 | 112.66 ± 157.91 |
| VZV-specific CD4 [2+] T-cells, Month 1 | 830.78 ± 775.61 | 1049.73 ± 2442.95 | 114.79 ± 114.03 | 146.91 ± 142.99 | 1049.36 ± 546.09 | 186.38 ± 31.21 |
| VZV-specific CD4 [2+] T-cells, Month 2 | 716.33 ± 699.22 | 991.07 ± 2190.70 | 814.64 ± 920.49 | 329.96 ± 53.46 | 769.13 ± 469.02 | 131.90 ± 185.13 |
| VZV-specific CD4 [2+] T-cells, Month 3 | 1973.47 ± 1669.57 | 1075.62 ± 2186.45 | 1804.94 ± 2350.96 | 408.18 ± 330.78 | 1298.35 ± 725.44 | 918.17 ± 1580.86 |
| VZV-specific CD4 [2+] T-cells, Month 6 | 1624.32 ± 1161.05 | 786.72 ± 657.24 | 1996.37 ± 1937.58 | 136.42 ± NA | 1160.93 ± NA | 42.92 ± 37.09 |
| VZV-specific CD4 [2+] T-cells, Month 7 | 2285.90 ± 1998.16 | 1261.84 ± 1946.12 | 6235.67 ± 4334.14 | 113.88 ± NA | 660.88 ± NA | — |
| VZV-specific CD4 [2+] T-cells, Month 18 | 1051.12 ± 816.86 | 599.00 ± 587.08 | 853.05 ± 1235.35 | 580.71 ± 683.08 | 634.55 ± 933.54 | 19.77 ± 22.14 |
| gE-specific CD4 [2+] T-cells, pre-vaccination | 215.99 ± 266.22 | 136.29 ± 176.85 | 51.15 ± 70.92 | 1.00 ± NA | 350.86 ± 161.96 | 26.57 ± 36.17 |
| gE-specific CD4 [2+] T-cells, Month 1 | 682.62 ± 595.89 | 134.21 ± 224.96 | 584.10 ± 652.67 | 161.73 ± 227.30 | 952.65 ± 763.24 | 84.33 ± 117.84 |
| gE-specific CD4 [2+] T-cells, Month 2 | 610.30 ± 558.27 | 157.92 ± 208.48 | 960.39 ± 632.86 | 94.19 ± 131.79 | 629.54 ± 513.99 | 1.00 ± 0.00 |
| gE-specific CD4 [2+] T-cells, Month 3 | 3722.21 ± 2789.70 | 190.58 ± 233.81 | 4754.94 ± 6004.05 | 1.00 ± 0.00 | 1310.76 ± 670.56 | 95.71 ± 164.04 |
| gE-specific CD4 [2+] T-cells, Month 6 | 2386.40 ± 1571.28 | 152.52 ± 141.50 | 5403.79 ± 3326.03 | 97.99 ± NA | 912.30 ± NA | 1.00 ± 0.00 |
| gE-specific CD4 [2+] T-cells, Month 7 | 3649.92 ± 3112.69 | 166.94 ± 150.54 | 14925.30 ± 10934.07 | 1.00 ± NA | 861.21 ± NA | — |
| gE-specific CD4 [2+] T-cells, Month 18 | 2071.17 ± 1583.58 | 159.05 ± 239.50 | 2035.18 ± 2100.82 | 109.97 ± 93.90 | 709.62 ± 1011.03 | 24.81 ± 47.63 |
Antibody concentrations were as determined by ELISA and tabulated for the main study groups. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.
| mIU/mL | GSK1437173A Group | Placebo Group |
|---|---|---|
| Anti-VZV, Pre-vaccination | 1292.7 (999.8 to 1671.4) | 1074.7 (672.7 to 1717.0) |
| Anti-VZV, Month 1 | 6953.8 (5425.1 to 8913.3) | 1173.8 (762.9 to 1805.8) |
| Anti-VZV, Month 2 | 5170.9 (4032.7 to 6630.4) | 987.6 (596.3 to 1635.8) |
| Anti-VZV, Month 3 | 11119.7 (9190.8 to 13453.3) | 1037.8 (620.2 to 1736.5) |
| Anti-VZV, Month 6 | 8244.0 (6678.6 to 10176.3) | 1069.8 (653.3 to 1751.7) |
| Anti-VZV, Month 7 | 14560.8 (11849.0 to 17893.1) | 999.3 (598.3 to 1669.2) |
| Anti-VZV, Month 18 | 7493.3 (5926.7 to 9473.9) | 922.9 (521.1 to 1634.6) |
| Anti-gE, Pre-vaccination | 1218.4 (895.0 to 1658.7) | 849.5 (551.1 to 1309.4) |
| Anti-gE, Month 1 | 24113.2 (18317.4 to 31743.0) | 1059.0 (749.4 to 1496.5) |
| Anti-gE, Month 2 | 17112.6 (12929.5 to 22649.1) | 903.3 (590.9 to 1380.9) |
| Anti-gE, Month 3 | 50443.0 (40899.6 to 62213.2) | 992.9 (647.4 to 1522.6) |
| Anti-gE, Month 6 | 34159.4 (27221.0 to 42866.2) | 1013.1 (660.5 to 1553.7) |
| Anti-gE, Month 7 | 63812.6 (51183.6 to 79557.7) | 1028.4 (658.9 to 1605.0) |
| Anti-gE, Month 18 | 25242.2 (19618.9 to 32477.3) | 918.0 (588.0 to 1433.1) |
Antibody concentrations were as determined by ELISA and tabulated by HIV status. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.
| mIU/mL | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| Anti-VZV, Pre-vaccination | 1161.5 (900.3 to 1498.6) | 985.1 (568.7 to 1706.4) | 2272.6 (559.1 to 9236.6) | 2511.9 (693.0 to 9104.4) | 1658.0 (315.9 to 8701.1) | 1068.5 (117.3 to 9735.4) |
| Anti-VZV, Month 1 | 7017.8 (5441.2 to 9051.3) | 1059.6 (641.1 to 1751.2) | 6731.0 (572.7 to 79107.0) | 2871.0 (1386.7 to 5944.3) | 6706.0 (2477.9 to 18148.5) | 1167.3 (130.1 to 10475.4) |
| Anti-VZV, Month 2 | 5056.5 (3973.9 to 6434.0) | 886.9 (498.6 to 1577.4) | 5649.6 (418.4 to 76276.9) | 2902.1 (1.9 to 4493973) | 6100.0 (480.4 to 77462.7) | 1191.1 (119.6 to 11860.7) |
| Anti-VZV, Month 3 | 11631.9 (9523.8 to 14206.6) | 1002.7 (565.8 to 1777.1) | 9110.7 (2224.8 to 37308.9) | 2479.3 (NA to NA) | 8990.7 (5233.1 to 15446.6) | 1062.0 (81.1 to 13906.2) |
| Anti-VZV, Month 6 | 9027.6 (7225.1 to 11279.6) | 957.0 (537.2 to 1705.0) | 7634.7 (2054.6 to 28369.5) | 3164.8 (510.5 to 19621.7) | 4384.3 (2322.5 to 8276.5) | 1006.3 (115.7 to 8754.6) |
| Anti-VZV, Month 7 | 15278.5 (12420.2 to 18794.5) | 930.5 (511.6 to 1692.3) | 14763.2 (2859.6 to 76216.1) | 2177.3 (8.7 to 544573.1) | 8845.8 (5463.6 to 14321.5) | 1076.7 (109.5 to 10591.1) |
| Anti-VZV, Month 18 | 8242.2 (6484.1 to 10476.9) | 838.1 (435.9 to 1611.5) | 6106.2 (748.6 to 49809.5) | 1955.3 (188.8 to 20249.5) | 4361.7 (1721.5 to 11050.9) | 1209.2 (13.9 to 105230.8) |
| Anti-gE, Pre-vaccination | 1113.2 (794.3 to 1560.3) | 791.0 (490.7 to 1275.1) | 1845.1 (465.1 to 7319.1) | 2420.7 (512.0 to 11445.2) | 1748.6 (308.5 to 9912.2) | 661.2 (43.8 to 9984.8) |
| Anti-gE, Month 1 | 25530.6 (19158.6 to 34021.9) | 1029.5 (719.5 to 1473.1) | 18767.2 (2219.4 to 158697.1) | 2328.1 (446.4 to 12141.8) | 18742.3 (6616.7 to 53089.1) | 720.0 (50.6 to 10238.5) |
| Anti-gE, Month 2 | 18208.6 (13537.4 to 24491.6) | 839.8 (524.6 to 1344.4) | 13106.4 (1619.0 to 106104.2) | 2465.5 (561.9 to 10817.4) | 13100.6 (4828.6 to 35543.7) | 735.0 (52.7 to 10245.9) |
| Anti-gE, Month 3 | 54777.7 (44077.1 to 68076.1) | 955.6 (590.6 to 1546.2) | 36592.6 (7026.0 to 190581.1) | 2166.3 (618.9 to 7583.1) | 33662.4 (20665.6 to 54833.0) | 736.6 (52.1 to 10414.5) |
| Anti-gE, Month 6 | 38068.2 (29964.3 to 48363.7) | 932.8 (582.6 to 1493.3) | 24725.0 (5143.2 to 118862.3) | 2629.2 (561.7 to 12306.8) | 18189.6 (11258.0 to 29389.0) | 920.6 (54.8 to 15461.5) |
| Anti-gE, Month 7 | 71309.6 (57019.3 to 89181.5) | 928.8 (566.8 to 1522.1) | 47382.6 (9151.2 to 245336.2) | 2553.0 (610.1 to 10683.1) | 32334.6 (17277.6 to 60513.4) | 1087.6 (60.2 to 19641.4) |
| Anti-gE, Month 18 | 28854.6 (22512.5 to 36983.3) | 849.4 (514.6 to 1401.9) | 18995.8 (1733.3 to 208181.4) | 1953.7 (572.7 to 6665.3) | 10869.2 (4435.4 to 26635.7) | 757.8 (34.8 to 16519.1) |
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications | 1 | 0 |
CD4 count was tabulated by HIV status.
| CD4 T-cells/million T-cells | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| CD4+, pre-vaccination | 631.46 ± 236.36 | 683.39 ± 228.29 | 152.11 ± 38.39 | 132.20 ± 11.19 | 805.33 ± 132.38 | 901.67 ± 177.61 |
| CD4+, Month 1 | 630.55 ± 241.78 | 694.69 ± 307.98 | 151.11 ± 38.72 | 163.00 ± 53.66 | 879.67 ± 277.37 | 773.40 ± 144.85 |
| CD4+, Month 2 | 667.69 ± 309.22 | 656.14 ± 262.43 | 131.13 ± 39.57 | 133.75 ± 31.86 | 808.75 ± 211.32 | 804.00 ± 199.09 |
| CD4+, Month 3 | 633.60 ± 228.75 | 640.14 ± 238.05 | 153.11 ± 54.27 | 142.60 ± 36.49 | 783.63 ± 239.92 | 762.60 ± 185.66 |
| CD4+, Month 6 | 655.02 ± 264.67 | 668.28 ± 308.64 | 145.33 ± 29.74 | 145.20 ± 43.18 | 776.43 ± 303.30 | 1082.80 ± 649.82 |
| CD4+, Month 7 | 654.69 ± 271.31 | 658.81 ± 246.53 | 170.25 ± 44.52 | 150.40 ± 35.11 | 869.14 ± 297.04 | 866.00 ± 144.30 |
| CD4+, Month 18 | 679.71 ± 247.57 | 651.06 ± 247.30 | 168.43 ± 58.49 | 151.40 ± 57.48 | 720.00 ± 228.77 | 824.40 ± 207.57 |
HIV VL was tabulated by HIV status, for subjects with a number of available results greater than or equal to (≥) 40 copies/mL.
| HIV-RNA copies/mL | Antiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173A | ART High CD4 Cohort - Placebo | ART Low CD4 Cohort - GSK 1437173A | ART Low CD4 Cohort - Placebo | Non-ART High CD4 Cohort - GSK 1437173A | Non-ART High CD4 Cohort - Placebo |
|---|---|---|---|---|---|---|
| HIV VL, pre-vaccination | — | — | 62.00 ± NA | — | 23014.11 ± 18435.10 | 16022.17 ± 23652.18 |
| HIV VL, Month 1 | 42.00 ± NA | — | 48.00 ± NA | — | 24538.89 ± 19056.10 | 14415.80 ± 9289.92 |
| HIV VL, Month 2 | 48.67 ± 10.79 | 55.00 ± NA | 48.00 ± 2.83 | — | 24134.25 ± 13753.92 | 18188.25 ± 15199.35 |
| HIV VL, Month 3 | 75.00 ± 37.75 | — | 84.00 ± NA | — | 19453.50 ± 11878.74 | 16270.00 ± 15785.91 |
| HIV VL, Month 6 | 19699.25 ± 39272.50 | 112.00 ± NA | 66053.50 ± 93328.90 | 51.00 ± NA | 37091.29 ± 33678.60 | 46429.60 ± 52567.42 |
| HIV VL, Month 7 | 530.67 ± 785.50 | 55.75 ± 6.29 | 248.00 ± NA | — | 35534.00 ± 39549.42 | 25774.60 ± 27360.66 |
| HIV VL, Month 18 | 70.33 ± 29.54 | 92.67 ± 64.53 | 48.00 ± NA | — | 60597.00 ± 48313.15 | 14742.60 ± 18306.17 |
Collected over Solicited local and general symptoms: within 7 days (Days 0-6) post-vaccination. Unsolicited Adverse Events (AEs): within 30 days (Days 0-29) post-vaccination. Serious Adverse Events (SAEs): during the entire study period (from Month 0 up to Month 18).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 0/74 (0%) | 6/74 (8.1%) | 72/74 (97.3%) |
| Placebo Group | 0/49 (0%) | 2/49 (4.1%) | 29/49 (59.2%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| Drug abusePsychiatric disorders | 0/74 | 1/49 |
| Peripheral vascular disorderVascular disorders | 0/74 | 1/49 |
| Anal abscessInfections and infestations | 1/74 | 0/49 |
| Coronary artery diseaseCardiac disorders | 1/74 | 0/49 |
| EpididymitisReproductive system and breast disorders | 1/74 | 0/49 |
| Laryngeal cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/74 | 0/49 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/74 | 0/49 |
| Partial seizuresNervous system disorders | 1/74 | 0/49 |
| Portal hypertensionHepatobiliary disorders | 1/74 | 0/49 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 72/73 | 6/48 |
| FatigueGeneral disorders | 55/73 | 14/48 |
| MyalgiaGeneral disorders | 54/73 | 9/48 |
| HeadacheGeneral disorders | 47/73 | 15/48 |
| ShiveringGeneral disorders | 37/73 | 5/48 |
| RednessGeneral disorders | 28/73 | 0/48 |
| GastrointestinalGeneral disorders | 28/73 | 11/48 |
| TemperatureGeneral disorders | 22/73 | 3/48 |
| SwellingGeneral disorders | 20/73 | 0/48 |
| Influenza like illnessGeneral disorders | 6/74 | 1/49 |
| Age, Continuous(Years) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 46.6 ± 10.68 | 45.1 ± 11.36 | 46.0 ± 10.93 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 69 | 47 | 116 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| African heritage/African American | 6 | 2 | 8 |
| Asian-East Asian heritage | 0 | 1 | 1 |
| Asian-Japanese heritage | 1 | 0 | 1 |
| White-Caucasian/European heritage | 66 | 42 | 108 |
| Unspecified | 1 | 4 | 5 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Sep 2010 to primary completion in Jul 2012, 21 months.
Results were first posted in Jun 2017, 4 years 11 months after primary completion. A results delay was requested in Apr 2013.
Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 21 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix